Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
Globe Newswire•16/11/2026•07:30 ET
0
Key Highlights
- ➤90 patients completed treatment in pivotal MIRACLE Part A for relapsed/refractory AML
- ➤Comprehensive MIRACLE Part A data readout remains on track for Q1 2027
- ➤Q3 net loss $6.5 million versus $25.4 million year over year
- ➤Cash and equivalents $7.3 million; nine-month operating cash use $21.7 million
- ➤Peer-reviewed analysis found no clinical or subclinical cardiotoxicity across 90 patients
Expert Statements
Walter Klemp, Chairman and Chief Executive Officer of Moleculin Biotech
“We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin Biotech
“Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement. We are now focused on delivering the comprehensive dataset in the first quarter of 2027, which we expect will provide important insights into Annamycin's clinical activity, safety and optimal dose for advancement into Part B. We are also looking forward to releasing quantitative market research data soon, further supporting the commercial opportunity for Annamycin”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin Biotech
“What gives us confidence as we approach this readout is the totality of evidence generated to date”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin Biotech
“We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy. We believe Annamycin has the potential to address a meaningful treatment gap in AML, and the upcoming Part A results represent an important opportunity to further evaluate that potential. Our priority is clear: execute on the data readout, make informed development decisions and advance Annamycin toward its next critical milestones.”
- Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML)
- Comprehensive Part A data readout remains on track for the first quarter of 2027, supporting optimal dose selection and planned initiation of Part B
Get started
Create a free account to read the full story.
